Brief: Daré Bioscience Provides Update On Activities To Support Commercial Launch Of XACIATO Vaginal Gel, 2%, FDA-Approved Treatment For Females 12 And Older With Bacterial Vaginosis

Dare Bioscience

05/07/2023 13:20

July 5 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE PROVIDES UPDATE ON ACTIVITIES TO SUPPORT
COMMERCIAL LAUNCH OF XACIATO™ (CLINDAMYCIN PHOSPHATE) VAGINAL
GEL, 2%, FDA-APPROVED TREATMENT FOR FEMALES 12 AND OLDER WITH
BACTERIAL VAGINOSIS
    * DARE BIOSCIENCE - REAFFIRMED COMMITMENT TO COMMERCIAL
LAUNCH OF
XACIATO VAGINAL GEL, 2% WITH ORGANON AND ORGANON WILL PAY CO
$1.0 MILLION IN JULY 2023

Source text for Eikon:  ID:nGNX79XvD6 
Further company coverage:  DARE.O 

 ((reuters.briefs@thomsonreuters.com;))